Patent: 6,419,944
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 6,419,944
Title: | Cytokine antagonists for the treatment of localized disorders |
Abstract: | Cytokine antagonists for use in localized clinical disorders are provided for the treatment and prevention of damage to the optic nerve, other cranial nerves, spinal cord, nerve roots, peripheral nerves or muscles caused by any one of the following: a herniated nucleus pulposus, osteoarthritis, other forms of arthritis, disorders of bone, disease, or trauma. The cytokine antagonists are used to treat these disorders by local administration. These cytokine antagonists include antagonists to tumor necrosis factor; interleukin-1; interleukin-6; and interleukin-8. |
Inventor(s): | Tobinick; Edward L. (Los Angeles, CA) |
Assignee: | |
Application Number: | 09/826,976 |
Patent Claims: | see list of patent claims |
Details for Patent 6,419,944
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | See Plans and Pricing | 2019-02-24 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | See Plans and Pricing | 2019-02-24 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | See Plans and Pricing | 2019-02-24 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | See Plans and Pricing | 2019-02-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |